Table 2: Univariate analysis of factors associated with “differentiated phenotype” in CD8+ HCMV-specific T cells.

ParameterAll patientsDifferentiated phenotype ( )Nondifferentiated phenotype ( )Univariate
OR (95% CI) value

Posttransplant HCMV replication ( , (%))
  Yes15 (57.7)11 (73.3)4 (26.6)3.3 (0.6–17.2)0.228
  No11 (42.3)5 (45.4)6 (54.5)
Donor age ( , (%))
  ≥4014 (53.8)12 (85.7)2 (14.3)12 (1.4–85.2)0.014
  <40 12 (46.2)4 (33.3)8 (66.7)
Recipient age ( , (%))
4015 (57.7)11 (73.3)4 (26.6)3.3 (0.6–17.2)0.228
40 11 (42.3)5 (45.4)6 (54.5)
Donor HCMV serology ( , (%))
  Positive14 (53.8)11 (78.6)3 (21.4)5.1 (0.9–28.6)0.105
  Negative12 (46.2)5 (41.6)7 (58.3)
Recipient HCMV serology ( , (%))
  Positive23 (88.5)16 (69.6)7 (30.4)15.4 (0.7–337.2)0.110
  Negative3 (11.5)0 (0)a3 (100)
Stem cell source ( , (%))
  Peripheral blood14 (53.8)10 (71.4)4 (28.6)2.5 (0.5–12.6)0.420
  Bone marrow12 (46.2)6 (50)6 (50)

OR: odds ratio. CI: confidence interval. “Differentiated phenotype” refers to patients with CD8+ T HCMV-specific cells, naive phenotype (CD45RA+CCR7+) ≤ 6.7% and CD28+ ≤ 30%. These cutoff values are the mean of all patients. values < 0.05 were considered statistically significant.
aWe have added 0.5 to categories with 0 individuals using EPIDAT 3.1 software.